Introduction: Tuberculosis (TB) and diabetes mellitus comorbidity can lead to poor TB treatment outcomes, particularly with uncontrolled blood glucose levels. Understanding the impact of glycemic control on TB treatment outcomes is essential.Objective: To synthesise evidence on the association between glycemic control and TB treatment outcomes in patients with TB and diabetes mellitus.Methodology: A systematic review was conducted using Medline, Embase, Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Google Scholar for all types of studies published between 1975 and May 2024, including adult TB patients of >18 years of age, with or without diabetes mellitus for whom blood glucose testing along with TB treatment outcome comparison with glucose levels (low/high) was reported were considered for inclusion. A random‐effects model was used for meta‐analysis, heterogeneity was assessed using I‐squared statistics, subgroup and sensitivity analysis was performed followed by publication bias assessment.Results: Of 576 identified studies, 12 met the inclusion criteria, analysing 2320 cases (1572 with uncontrolled high blood glucose [≥7% HbA1c] and 748 with controlled low blood glucose [<7% HbA1c]). Low certainty evidence shows that patients with uncontrolled high glucose had a 1.91 times higher risk of TB treatment failure (risk ratios [RR] = 1.91, 95% confidence interval [CI] 1.81–3.07, p = 0.008), and a 2.97 times higher risk of sputum positivity at 3 months (RR = 2.97, 95% CI 1.10–8.07, p = 0.03). Subgroup and sensitivity analyses showed significant improvement in pooled effects, lowering of heterogeneity and narrower CIs. For overall pooled effect, substantial heterogeneity was observed; therefore, the interpretation and generalisation of results should be done with caution.Conclusion: A low certainty evidence shows that uncontrolled high blood glycemic level significantly impacts TB treatment outcomes, increasing treatment failure and sputum positivity among TB patients with diabetes mellitus.
Introduction People with tuberculosis (TB) who continue to smoke are more likely to have poor health outcomes than those who quit. Established smoking cessation approaches such as mHealth may help patients with TB quit smoking. This paper summarises the methodology proposed to assess the effectiveness and cost-effectiveness of mTB-Tobacco (an mHealth intervention) in helping patients with TB stop smoking and have improved health outcomes. Methods and analysis A two-arm, parallel, open-label, multicentre, cluster randomised, two-stage adaptive design trial is proposed to first evaluate the superiority of mTB-Tobacco, compared with usual care and then the non-inferiority of mTB-tobacco compared with face-to-face behaviour support. Study settings include TB treatment centres in Bangladesh and Pakistan. The study population includes adult patients, newly diagnosed (within 4 weeks) with pulmonary TB disease, daily smokers, willing to quit and have access to mobile phones. The primary outcome includes biochemically verified continuous smoking abstinence assessed at 6 months per Russell Standard. A generalised linear mixed-effects model will be used to assess the impact of mTB-Tobacco intervention on continuous outcomes, incorporating fixed effects for the intervention, random effects for clusters and relevant covariates. Cost-effectiveness analysis will be done to estimate the cost per quitter and cost per quality-adjusted life year gained, calculate the incremental cost-effectiveness ratios to establish the value for money for mTB-Tobacco. Ethics and dissemination This trial will be conducted in compliance with International Council on Harmonisation - Good Clinical Practice guidelines and the Declaration of Helsinki. The study has been approved by the ethics committees of the University of Edinburgh Medical School Research Ethics Committee (EMREC) of UK, the Bangladesh Medical Research Council (BMRC) and the National Bioethics Committee (PMRC) of Pakistan. The results of this trial will be disseminated in peer-reviewed journals and presented in academic conferences. Trial registration number ISRCTN86971818 (https://doi.org/10.1186/ISRCTN86971818); pre-enrolment, submission date: 29 August 2023; registration date: 11 September 2023.
Objective: To determine the severity of acute respiratory infections in children by using Pediatric Respiratory Severity Score (PRESS). Methodology: This descriptive cross sectional study was conducted at the outpatient and emergency paediatric department of the Federal Govt. Polyclinic hospital, Islamabad, from October 2017 to December 2019. One hundred and seventeen children with acute respiratory infections were enrolled in the study by a non-probability sampling technique. Epidemiologic variables of interest included age, sex, and breastfeeding or not. Clinical variables of interest included respiratory rate, use of accessory respiratory muscle, wheeze on auscultation, and oxygen saturation at room air.  PRESS assessed tachypnea, wheezing, accessory muscle use, SpO2 and feeding difficulties with each component given a score of 0 or 1, and the total score were categorized as a mild(0-1), moderate (2-3) or severe(4-5). Results: Out of 117 children, 98 (83.8%) belonged to the age group > 2 months– 12 months, while 19 (16.2%) belonged to the age group > 12 months– 24 months. Among them, 17 (14.5%) were mild, 53 (45.3%) were moderate, and 47 (40.2%) were severe according to their severity of respiratory distress. The hospitalization rate for moderate infection was 84.9% while 100% for severe infection and none of the patient with mild infection was hospitalized (p<0.001). Conclusion: Early assessment by simple bedside technique will help in managing the respiratory distress according to its severity, reducing the undue investigation and improving the outcome of illness. Moreover it can be easily administered at primary health care facilities for triage of pediatric patients with respiratory distress.
Air quality refers to the cleanliness of the air, whereas air pollution is the presence of harmful chemical, physical, or biological substances in the atmosphere [1]. Common pollutants include particulate matter (PM), nitrogen oxides, ozone, sulphur oxides, carbon monoxide (CO), and lead. Major sources of air pollution include motor vehicle emissions, industrial processes, household combustion, […]
1 January 2023 in International Journal of Surgery